Draft:Michael A. Cahill
Australian Biochemist and Cell Biologist
From Wikipedia, the free encyclopedia
Michael A. Cahill is a retired Australian biochemist, cell biologist, and proteomics researcher. He is best known for his contributions to research on the progesterone receptor membrane component 1 (PGRMC1) protein, including its differential phosphorylation in cancer cells, roles in cellular metabolism and signaling, and potential implications for cancer and Alzheimer's disease.[citation needed]
Submission declined on 13 May 2026 by Devonian Wombat (talk). This draft is not written from a neutral point of view. Wikipedia articles must be written neutrally in a formal, impersonal, and dispassionate way. They should not read like a blog post, advertisement, or fan page. Rewrite the draft to remove:
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
This draft lacks inline citations. Wikipedia's verifiability policy requires that all content be supported by reliable sources. We require inline citations (footnotes) to show which source supports which specific statement.
Declined by Dan arndt 4 months ago.You must place an inline citation directly after:
Please edit your draft to support your statements with inline citations. Learn how to create inline citations in the:
| |
Comment: In accordance with Wikipedia's Conflict of interest guideline, I disclose that I have a conflict of interest regarding the subject of this article. ~2026-24302-37 (talk) 08:54, 20 April 2026 (UTC)
Early life and education Cahill earned a Bachelor of Science with First Class Honours (BSc Hons 1) in Zoology and Biochemistry from the University of New South Wales (UNSW), Sydney, Australia. He completed his PhD (awarded 1996) through the School of Pathology at UNSW's Faculty of Medicine. His doctoral research was conducted primarily at the Medizinische Hochschule Hannover in Germany under Prof. Alfred Nordheim and focused on the structural and functional analysis of the serum response factor (SRF) in signal transduction and gene regulation.[1]
Career Early research and postdoctoral work Following his studies, Cahill conducted doctoral and postdoctoral research in Germany on signal transduction pathways, including those involving the c-fos promoter and serum response element. He later held a postdoctoral position at the John Curtin School of Medical Research at the Australian National University before returning to the University of Tübingen, where he established a proteomics research group.[citation needed]
ProteoSys AG In 2000, Cahill co-founded ProteoSys AG, a biotechnology company in Mainz, Germany, specializing in proteomics technologies for cancer research. As Chief Research Officer and a member of the managerial board, he led the team that discovered differential phosphorylation of PGRMC1 in cancer tissues.[2] This work led to patent applications regarding phosphorylated membrane progesterone receptors as potential diagnostic markers or therapeutic targets. He left the company in 2007. [3]
Academic positions in Australia In 2008, Cahill joined Charles Sturt University (CSU) in Wagga Wagga, New South Wales, as a Lecturer in Biochemistry and Molecular Cell Biology in the School of Biomedical Sciences. He taught undergraduate and postgraduate courses, coordinated honours programs, and was elected to the university's Academic Senate in 2016. His research at CSU continued to focus on PGRMC1 functions in cell biology, metabolism, glycolysis, cell motility, and tumor biology, often through international collaborations. He left his full-time position in January 2021.[4]
Advisory and honorary roles Cahill served on the Scientific Advisory Board of Cognition Therapeutics Inc. in the United States, contributing expertise on PGRMC1 and its interactions with the sigma-2 receptor complex (including TMEM97) in relation to amyloid-beta oligomer binding and potential Alzheimer's disease therapies.[citation needed] He has held honorary or adjunct academic positions at institutions including the Australian National University and Charles Sturt University.[5]
Research contributions Cahill's early work examined signal transduction cascades converging on transcription factors such as SRF and the regulation of immediate early genes like c-fos. He later applied proteomics approaches to cancer biology.[6]
His most prominent research concerns PGRMC1, a heme-binding protein implicated in progesterone signaling, cellular metabolism, and disease processes. Key areas include: Differential phosphorylation of PGRMC1 in cancer and its effects on cell shape, motility, and tumor growth. Interactions with other proteins, potential roles in heme transfer, cholesterol/steroid binding, and metabolic regulation (e.g., glycolysis). Broader implications for breast cancer, pancreatic cancer, and neurodegenerative conditions. He has authored integrative reviews on PGRMC1 and collaborated on studies exploring it as a potential therapeutic target. [7] [8]
Other activities In addition to his scientific work, Cahill has authored books on topics including the roots of civilization (e.g., Paradise Rediscovered).[9]
- provide significant coverage: discuss the person in detail, not brief mentions or interviews lacking independent analysis;
- are reliable: from reputable outlets with editorial oversight;
- are independent: not connected to the person, such as interviews, press releases, the subject's own website, or sponsored content.
Please add references that meet all three of these criteria. If none exist, the subject is not yet suitable for Wikipedia.